查詢結果分析
相關文獻
- Lamotrigine as Add-On Therapy in Adult Patients with Refractory Epilepsy
- Proton Chemical Shift Imaging of the Hippocampus in Patients with Complex Partial Seizures
- 以迷走神經刺激治療局部發作癲癇
- An Unusual Case of Tuberculous Meningitis
- Role of Foramen Ovale Electrodes in Presurgical Evaluation of Intractable Complex Partial Seizures
- 頑性癲癇之手術治療
- Proton Magnetic Resonance Spectroscopy in Patients with Complex Partial Seizures
- 癲癇
- 癲癇之神經外科手術治療(兼論癲癇侵入性術前評估與手術)
- 小兒頑性癲癇之外科治療新觀念
頁籤選單縮合
題名 | Lamotrigine as Add-On Therapy in Adult Patients with Refractory Epilepsy=成人頑性癲癇病患之Lamotrigine附加治療 |
---|---|
作 者 | 顏得楨; 姚俊興; 關尚勇; 林永煬; 蘇明勳; | 書刊名 | 中華醫學雜誌 |
卷期 | 59:5 1997.05[民86.05] |
頁次 | 頁303-307 |
分類號 | 418.21 |
關鍵詞 | Lennox-gastaut症候群; 局部癲癇; 頑性癲癇; Lamotrigine; Lennox-gastaut syndrome; Partial seizure; Refractory epilepsy; |
語文 | 英文(English) |
中文摘要 | 背景:Lamotrigine(LTG)為一新型口服抗癲癇藥物。附加使用或單獨使用LTG之臨床試用研究,顯示其能有效控制局部癲癇及泛發性癲癇。為評估其臨床療效及安全性,我們將其附加使用於41位國內滿16歲之頑性癲癇病人,其中包括5位Lennox-Gastaut症候群及36位局部癲癇病人。 方法:LTG之給藥方式,依病人是否正在使用valproate(VPA)而異。已使用VPA之病人,LTG從每日25毫克開始服用;未使用此藥者從50毫克開始。隨後,按週逐漸增加LTG至最高劑量(每日200毫克或400毫克),然後維持此劑量至三個月。試用期間,其他先前正在使用之抗癲癇藥物,其種類與劑量維持不變。LTG臨床療效之評估,主要依據是試用前後癲癇發作次數減少之比率。至於其臨床安全性,則視副作用發生之機率與試用前後抽血檢驗一般血液及生化常規之比較而定。 結果:在完成試用之38位病人中,有22位(57.9%)之癲癇發作次數減少達到一半以上。此中包括4位Lennox-Gastaut症候群及18位局部癲癇病人。LTG對局部癲癇之改善效果,與癲癇病灶在顳葉區域內或顳葉區域外,兩者間並無差異(p = 0.577)。LTG之療效,亦與病人是否已經使用VPA無顯著關連(p = 0.189)。13位(31.7%)試用者有輕微不適情形發生;大多與劑量有關,經減藥即可改善。只有兩人(4.9%)因嚴重之副作用,而需停用此藥。在血液及生化常規檢查方面,所有病人皆無明顯變化。 結論:LTG附加使用於頑性Lennox-Gastaut症候群及局部癲癇病人,可改善其原療法之治療效果,且無嚴重副作用。 |
英文摘要 | Background: Lamotrigine (LTG), one of the newly developed antiepileptic drugs, is efficacious in treating both partial and generalized seizure disorders including Lennox-Gastaut syndrome. Its effect as an add-on therapy was evaluated in 41 adult Chinese patients with refractory epilepsy. Five of the patients were Lennox-Gastaut syndrome and 36 patients had partial epilepsy. Methods: We started LTG at 25mg or 50mg per day, respectively, depending on whether the patients were simultaneously taking valproate (VPA) or not. Then, LTG was increased in steps to maximal dosage (200mg or 400mg per day) within seven weeks and maintained for three months while pre-existing antiepileptic drugs remained unchanged. The efficacy of LTG therapy was assessed by the reduction in the overall seizure frequency. Hematological and biochemical parameters were checked before and after the trial in all patients. Results: In all, 38 patients completed the trial. Twenty-two patients (57.9%) had >= 50% reduction in seizure frequency, including four patients with Lennox-Gastaut syndrome and 18 patients with partial seizures. Among the patients with partial epilepsy, there was no significant difference in the efficacy of LTG whether the seizures were of temporal or extra-temporal origin (p =0. 577). In addition, the efficacy was not determined by the concomitant use of VPA (p =0.189). Thirteen patients (31.7%) complained of adverse experiences, usually mild and dose-dependent. LTG had to be discontinued in only two patients (4.9%) due to severe side effects. The change in blood cell counts and biochemistry profiles was not significant in any of the patients. Conclusions: We conclude that LTG is an efficacious and safe antiepileptic drug for add-on therapy in adult patients with refractory epilepsy. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。